TY  - GEN
AU  - Doria,A
AU  - Stohl,W
AU  - Schwarting,A
AU  - Okada,M
AU  - Scheinberg,M
AU  - van Vollenhoven,R
AU  - Hammer,A E
AU  - Groark,J
AU  - Bass,D
AU  - Fox,N L
AU  - Roth,D
AU  - Gordon,D
TI  - Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
SN  - 2326-5205
PY  - 2019///0722
KW  - Adult
KW  - Antibodies, Antinuclear
KW  - blood
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Complement C3
KW  - deficiency
KW  - DNA
KW  - immunology
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Injections, Subcutaneous
KW  - Intention to Treat Analysis
KW  - Lupus Erythematosus, Systemic
KW  - Male
KW  - Severity of Illness Index
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1002/art.40511
ER  -